Specifically, in pleural mesothelioma (PM), the accuracy of MSLN as a biomarker has been evaluated across different matrices (mostly serum, plasma, and pleural fluids) and among different groups of individuals (mesothelioma patients, individuals affected by benign respiratory diseases, and healthy subjects). The gene discussed is MSLN; the disease is mesothelioma.